Loading...
•
Mar 31, 2023
Aurinia Q1 2023 Earnings Report
Reported a successful quarter with significant revenue growth and progress across commercial, R&D, and intellectual property.
Key Takeaways
Aurinia Pharmaceuticals reported a strong first quarter in 2023, with net revenue reaching $34.4 million, a 59% increase compared to the same period last year. The company is increasing its full-year revenue guidance to $135 - $155 million.
Net revenue for Q1 2023 was $34.4 million, a 59% increase year-over-year.
Net product revenue for Q1 2023 was $34.3 million, compared to $21.5 million in the prior year quarter.
Approximately 1,731 patients were on LUPKYNIS therapy as of March 31, 2023, compared to 1,071 at March 31, 2022.
The company is increasing its net product revenue guidance to a range of $135 - $155 million for 2023.
Revenue by Segment
Forward Guidance
The Company is increasing its net product revenue guidance to a range of $135 - $155 million from $120 - $140 million for net product sales of LUPKYNIS.
Positive Outlook
- Increased revenue guidance for 2023 to $135 - $155 million.
- Based on assumptions regarding historical patient start form (PSF) run rates
- Based on consistent conversion rates
- Based on time to convert
- Based on persistency, and pricing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...